[{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mundipharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Alpha Bioresearch | Dynamic Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mundipharma \/ Alpha Bioresearch | Dynamic Solutions","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Alpha Bioresearch | Dynamic Solutions"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"||antineoplastics (chloroethylamine derivatives)","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"||Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Biosolution","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharma \/ Biosolution"}]

Find Clinical Drug Pipeline Developments & Deals by Mundipharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for invasive candidiasis in adults.

                          Product Name : Rezzayo

                          Product Type : Other Small Molecule

                          Upfront Cash : $39.0 million

                          December 02, 2024

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Cidara Therapeutics

                          Deal Size : $568.0 million

                          Deal Type : Partnership

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the divestment, Mundipharma received the rights for Rezzayo (rezafungin acetate), an echinocandin antifungal, approved for the treatment of invasive candidiasis in adults.

                          Product Name : Rezzayo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 24, 2024

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Cidara Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The collaboration aims to reformulate flutiform (fluticasone propionate/formoterol fumarate) used in a pressurised metered-dose inhaler. It is being indicated for asthma.

                          Product Name : Flutiform

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Vectura Ltd

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.

                          Product Name : Flutiform

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Vectura Ltd

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 22, 2023

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 13, 2023

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Cidara Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 28, 2023

                          Lead Product(s) : Rezafungin,Septrin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidi...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2022

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 09, 2022

                          Lead Product(s) : Rezafungin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank